-

COTA and Texas Oncology Collaborate to Advance AI-Enabled Precision Medicine

NEW YORK--(BUSINESS WIRE)--COTA, Inc., in collaboration with Texas Oncology’s Precision Health Informatics, LLC (PHI), announces an innovative collaboration aimed at revolutionizing precision medicine across Texas Oncology’s community cancer centers. Leveraging COTA’s AI-powered curation engine, CAILIN™, this collaboration will transform fragmented healthcare data into actionable insights.

Unlocking Insights from Electronic Health Records (EHRs)

Electronic health records contain a comprehensive account of a patient’s cancer care journey. However, their unstructured and incomplete format poses challenges for analysis. By infusing AI into data processing, COTA and PHI aim to accelerate precision medicine at the point of care.

High-Quality Data as the Foundation

Lori Brisbin, chief operating officer of Precision Health Informatics, emphasizes the importance of clean, accurate data: “As we invest in AI, a solid data foundation is crucial. COTA’s AI-powered curation engine enables Texas Oncology to derive meaningful insights and deliver personalized care to patients.”

Generative AI and Real-World Data

Dr. C.K. Wang, chief medical officer at COTA, highlights the promise of generative AI: “By meshing automation and supervision of high-quality real-world data (RWD), COTA is changing the dynamics of cancer care.”

About Precision Health Informatics and Texas Oncology

Precision Health Informatics, a Texas Oncology subsidiary, uses patients’ genetic information for innovative cancer testing and treatment. Its data-driven solutions are based on insights from a diverse patient base. Learn more at Precisionhealthinformatics.com.

Texas Oncology, with more than 530 physicians and 280 locations, provides comprehensive, community-based cancer care. Its robust clinical trials and research program has contributed to over 100 FDA-approved cancer therapies. Visit TexasOncology.com for more information.

About COTA, Inc.

Founded by oncologists, COTA focuses on precise, patient-first cancer care using real-world data. Their advanced analytics platform partners with life sciences companies, providers, and payers to improve cancer treatment. Learn more at cotahealthcare.com.

Contacts

Media
Dori Young
Email: Dori@12080group.com

Industry:

COTA, Inc.

Release Versions
English

Contacts

Media
Dori Young
Email: Dori@12080group.com

More News From COTA, Inc.

COTA and Guardant Health Partner to Advance Precision Oncology Research and Therapy Development with Real-World Clinicogenomic Data and AI Analytics

NEW YORK--(BUSINESS WIRE)--COTA Inc., a leader in real-world data (RWD) and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. (Nasdaq: GH) that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s clinicogenomic testing data to accelerate the development of new cancer therapies. Using the extensiv...

Research from COTA and leading global cancer center demonstrate how Real-World Data can fill cancer care gaps for older patients

NEW YORK--(BUSINESS WIRE)--COTA, Inc., a leader in real-world data (RWD) and analytics for oncology, and Memorial Sloan Kettering Cancer Center (MSK) today announced that data from two Diffuse Large B-Cell Lymphoma (DLBCL) studies in older patients will be presented at the upcoming 66th American Society of Hematology Annual Meeting (ASH), held December 7-10, 2024, in San Diego and virtually. The joint research explores the implication of treatment urgency and end-of-life care patterns for older...

COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™

NEW YORK--(BUSINESS WIRE)--Today, COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast™ (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence. One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. An accurate understanding of a patient’s prognosis is needed to inform treatment decisions. Risk assessment to determi...
Back to Newsroom